Clinical Research Directory
Browse clinical research sites, groups, and studies.
Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company
Summary
Obstructive jaundice is observed in 10-80 % of gallstone disease cases. The conventional tactics for the management of patients with obstructive jaundice is to remove biliary hypertension by using endoscopic or minimally invasive methods. The final surgical treatment is performed after jaundice reduction and normalization of hepatic functions. We suppose that the administration of the drug Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid) during the perioperative period shortens jaundice duration and decreases the complications rate.
Official title: Observational Study of Efficiency of the Drug Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
286
Start Date
2022-12-01
Completion Date
2025-12
Last Updated
2025-04-20
Healthy Volunteers
No
Conditions
Interventions
Remaxol
The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
Locations (9)
Krai Clinical Hospital
Barnaul, Russia
Hospital for War Veterans
Kazan', Russia
City Clinical Hospital No. 7
Nizhny Novgorod, Russia
Pavlov Ryazan State Medical University
Ryazan, Russia
Dzhanelidze St. Petersburg Research Institute of Emergency Medicine
Saint Petersburg, Russia
St. Elizabeth Hospital
Saint Petersburg, Russia
Samara State Medical University
Samara, Russia
Mirotvortsev University Clinical Hospital No. 1
Saratov, Russia
Kuvatov Republican Clinical Hospital
Ufa, Russia